RRRachel Melo Ribeiro

Rachel Melo Ribeiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rachel Melo Ribeiro has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic Potential of Fridericia platyphylla (Cham.) L.G. Lohmann: An Integrative Review of the Effects of Crude Extracts and Isolated Phytochemicals in Different Experimental Models

    by Andressa Coelho Ferreira, Raphael Furtado Marques, Icaro Rodrigo Dutra Cunha, Jhonata Costa Moura, Rebekha Matos Oliveira, Kellen De Jesus Farias Da Luz, Ludmila Tavares dos Santos Silva, Mateus Balbino Barbosa de Carvalho, Lara Possapp Andrade, Júlia Karla de Albuquerque Melo Xavier, et al.

    Fridericia platyphylla (Cham.) L.G. Lohmann is a species endemic to the Brazilian Cerrado, commonly known as “cervejinha do campo,” “cipó-una,” or ‘tintureiro,” traditionally used to treat kidney stones and joint pain. This species has garnered scientific interest due to its potential pharmacological properties. This review evaluated the pharmacological effects of crude extracts and isolated compounds from F. platyphylla, as well as its ethnopharmacological relevance. A comprehensive literature search was conducted across PubMed, Scielo, and Google Scholar for studies published between October 2014 and December 2024, using the descriptors “F. platyphylla” and “A. brachypoda” combined with terms related to in vivo, in vitro, and ethnopharmacological research. Of 896 records, 20 studies met the inclusion criteria. The included studies conducted comprehensive isolation and structural elucidation of the bioactive compounds, confirming their chemical identities and supporting their pharmacological relevance through robust analytical and spectroscopic validation. Different extracts and isolated compounds from the roots, leaves, and flowers of F. platyphylla have antiulcerogenic, antitumor, antiproliferative, anti-inflammatory, and antifungal action. Brachydins demonstrated cytotoxicity against prostate cancer cells and exhibited biological potential against intracellular amastigotes of Trypanosoma cruzi. Luteolin reduced proliferation in U-251 glioblastoma cells with low toxicity to nontumor cells. Additionally, the microemulsion and encapsulation of the active fraction obtained from the roots of this plant showed relevant biological activity for pharmaceutical applications. However, despite these promising findings, potential mutagenic effects raise concerns about the safety of using the plant. In conclusion, F. platyphylla and its phytochemicals hold significant therapeutic and technological potential. Nevertheless, further in vivo studies are necessary to ensure safety and better understand its pharmacological mechanisms, thereby paving the way for the development of novel therapeutic agents derived from this species.


  • Open Access

    Mycobacterium abscessus subsp. massiliense: Biofilm Formation, Host Immune Response, and Therapeutic Strategies

    by Roseane Lustosa de Santana Lira, Flávio Augusto Barros Nogueira, Rosália de Fátima Penna de Carvalho Campos, Dayenne Regina Mota Ferreira, Pedro Lucas Brito Tromps Roxo, Caio César Santana de Azevedo, Eleonôra Costa Monteiro Gimenes, Ruan Lucas Costa Bastos, Camila Evangelista Carnib Nascimento, Flávia Danyelle Oliveira Nunes, et al.

    Infection by Mycobacterium abscessus subsp. massiliense poses a growing public health threat, especially to immunocompromised individuals. The pathogenicity of this mycobacterium is directly linked to its ability to form biofilms, complex structures that confer resistance to antibiotics and the host immune response. The extracellular matrix of the biofilm acts as a physical barrier, hindering the penetration of drugs and the action of the immune system, while also inducing a slow-growth state that reduces susceptibility to antibiotics. Current therapies, which involve prolonged use of multiple antibiotics, are often ineffective and cause significant side effects. Therefore, it is essential to explore new strategies targeting bacterial resistance and biofilm destruction. This narrative review explores the biofilm-forming capacity of Mycobacterium abscessus subsp. massiliense and the potential of novel therapeutic strategies. Promising approaches include inhibiting biofilm formation, developing drugs with improved penetration of the extracellular matrix, combination therapies with agents that destabilize the biofilm structure, and modulating the host immune response. Investing in research and development of new therapeutic strategies is essential to combat this resistant bacterium and improve patient outcomes.


  • The role of physical exercise in modulating microRNAs expression in acute myocardial infarction: a review

    by Raphael Furtado Marques, Marcelo Souza de Andrade, Andressa Coelho Ferreira, Carlos José Moraes Dias, Nivaldo de Jesus Silva Soares Junior, Carlos Alberto Alves Dias Filho, Rachel Melo Ribeiro

    MicroRNAs (miRNAs) have emerged as promising tools for diagnosis and treatment in numerous pathophysiological processes, including cardiovascular diseases (CVD). In this context, acute myocardial infarction (AMI) is one of the leading causes of death by CVD worldwide. In this sense, physical exercise (PE) is considered a non-pharmacological strategy to reduce the complex alterations in AMI. This study is an integrative review of the literature to explore the effects of PE on the cardiomyocyte post-AMI, including an understanding of the mechanisms by which the PE acts on the miRNAs expression. A review was performed on PubMed, Scopus, and Web of Science. After the searches, all records were imported into the Mendeley software, and duplicate articles were removed. The year of publication of the papers was not limited. 19 studies were performed on animal models, 10 in experimental models using rats, and 08 in models with mice and only one study was carried out on patients with AMI. The results showed the potential use of miRNAs as diagnostic tools and attractive biomarkers for treating AMI. In addition, PE can regulate miRNAs expression in the myocardial cell, promotes apoptosis resistance, autophagy regulation, lower cardiac fibrosis and cardiac hypertrophy, and higher angiogenesis through the signaling of miRNAs. The main microRNAs mitigating the deleterious effects of AMI and modulated by PE were miRNA-222, miRNA-1192, miRNA-146, and miRNA-126. PE modulates the expression of specific miRNAs that support cardiac function, promoting cardioprotective effects or facilitating cardiac recovery post-AMI.


  • Open Access

    Nanotechnological Formulation Incorporating Pectis brevipedunculata (Asteraceae) Essential Oil: An Ecofriendly Approach for Leishmanicidal and Anti-Inflammatory Therapy

    by Estela Mesquita Marques, Lucas George Santos Andrade, Luciana Magalhães Rebelo Alencar, Erick Rafael Dias Rates, Rachel Melo Ribeiro, Rafael Cardoso Carvalho, Glécilla Colombelli de Souza Nunes, Daniele Stéfanie Sara Lopes Lera-Nonose, Maria Julia Schiavon Gonçalves, Maria Valdrinez Campana Lonardoni, et al.

    Cutaneous leishmaniasis caused by Leishmania amazonensis is a significant public health issue. This study aimed to evaluate an ecofriendly, thermosensitive nanogel, developed using a low-energy, solvent-free method, incorporating F127 and Carbopol 974P copolymers, and enriched with Pectis brevipedunculata essential oil (EOPb) for its leishmanicidal and anti-inflammatory properties. The nanogel was prepared and characterized through FTIR, DLS, SEM, and AFM to confirm the incorporation of EOPb as well as its stability and rheological properties. In vitro leishmanicidal activity was evaluated on Leishmania amazonensis promastigotes, and in vivo anti-inflammatory effects were assessed using a rat paw edema model. In vitro, nGF3 (EOPb-loaded nanogel) demonstrated significant leishmanicidal activity, with promastigote mortality rates exceeding 80% at 24 h and 90% at 48 h. In vivo, nGF1, nGF2, and nGF3 exhibited anti-inflammatory effects, with nGF2 and nGF3 reducing edema by 62.7% at 2 h post-treatment. The empty nanogel (nGF0) showed minimal anti-inflammatory activity. The ecofriendly EOPb-loaded nanogel (nGF3) demonstrated strong leishmanicidal and anti-inflammatory effects, presenting a promising candidate for cutaneous leishmaniasis treatment. Further studies are necessary to explore its clinical potential.


  • Open Access

    Plant-derived compounds with antineoplastic activity: a literature review

    by Matheus Bastos Vasconcelos, Mayron Guedes Silva, Raphael Guedes Silva, Vanessa Romano Uchoa, Naíme Diane Sauaia Holanda Silva, José Renzo Castro Garcês, Eduardo Rodrigues Silva, Jhonata Costa Moura, Ellen Caroline da Silva Penha, Andressa Coelho Ferreira, et al.

    Natural products, especially those derived from plants used in traditional medicine, are a significant source of novel therapeutics. Numerous plant-derived molecules have been extensively documented in scientific literature for their potential antineoplastic effects, acting through various mechanisms. This review highlights the most frequently cited antineoplastic compounds over the past 12 years: emodin, genistein, luteolin, parthenolide, quercetin, resveratrol, and betulinic acid. The aim is to provide an overview of these compounds, their plant origins, and their mechanisms of action. Studies were selected from the PubMed, SciELO, LILACS, and Google Scholar databases using the DeCS/MeSH descriptors relevant to the guiding question. All included studies evaluated the antitumor activity of these compounds through various experiments reported in the literature, demonstrating their efficacy against different cancer cell lines. The compounds exhibited cytotoxic and pro-apoptotic activities, inhibited cell viability, proliferation, and migration, and reduced resistance to existing antineoplastic drugs. These findings illustrate the anticancer pharmacological potential of the compounds under investigation and highlight the necessity for further clinical studies on these molecules to facilitate their future application in cancer therapy.

  • Open Access

    Nanotechnological formulation Incorporating Pectis brevipedunculata (Asteraceae) Essential Oil: An Ecofriendly Approach for Leishmanicidal and Anti-Inflammatory Therapy

    by Renato Sonchini Gonçalves, Estela Mesquita Marques, Lucas George Santos Andrade, Luciana Magalhães Rebelo Alencar, Erick Rafael Dias Rates, Rachel Melo Ribeiro, Rafael Cardoso Carvalho, Glécilla Colombelli De Souza Nunes, Daniele Stéfanie Sara Lopes Lera-Nonose, Maria Julia Schiavon Gonçalves, et al.

    Background/Objectives: Cutaneous leishmaniasis caused by Leishmania amazonensis is a significant public health issue. This study aimed to evaluate an eco-friendly, thermosensitive nanogel, developed using a low-energy, solvent-free method, incorporating F127 and Carbopol 974P copolymers, and enriched with Pectis brevipedunculata essential oil (EOPb) for its leishmanicidal and anti-inflammatory properties. Methods: The nanogel was prepared and characterized through FTIR, DLS, SEM, and AFM to confirm the incorporation of EOPb, stability and rheological properties. In vitro leishmanicidal activity was evaluated on Leishmania amazonensis promastigotes, and in vivo anti-inflammatory effects were assessed using a rat paw edema model. Results: In vitro, nGF3 (EOPb-loaded nanogel) demonstrated significant leishmanicidal activity, with promastigote mortality rates exceeding 80% at 24 h and 90% at 48 h. In vivo, nGF1, nGF2, and nGF3 exhibited anti-inflammatory effects, with nGF2 and nGF3 reducing edema by 62.7% at 2 h post-treatment. The empty nanogel (nGF0) showed minimal anti-inflammatory activity. Conclusions: The eco-friendly EOPb-loaded nanogel (nGF3) demonstrated strong leishmanicidal and anti-inflammatory effects, presenting a promising candidate for cutaneous leishmaniasis treatment. Further studies are necessary to explore its clinical potential.

  • Open Access

    Evidências científicas do potencial farmacológico dos probióticos na saúde cardiovascular

    by José Renzo Castro Garcês, Eduardo Rodrigues Silva, João Paulo Alves Pereira, Jhonata Costa Moura, Raphael Ferreira Faleiro, Ellen Caroline da Silva Penha, Andressa Coelho Ferreira, Raphael Furtado Marques, Ênio Fernandes Aragão Soares, Ahirlan Silva de Castro, et al.

    Dados recentes reportados pela literatura mostram que 45% dos óbitos globais por Doenças Crônicas Não Transmissíveis são atribuídos a doenças cardiovasculares (DCV), com as desordens isquêmicas cardíacas, sendo as principais causas de morte mundial. Estudos indicam uma possível relação entre o uso contínuo de probióticos e a saúde cardiovascular. Esta revisão integrativa examinou artigos originais sobre o uso de probióticos como prevenção para DIC. A pesquisa incluiu artigos publicados nas bases Medline/PubMed e Scielo entre 2012 e 2023, utilizando os Descritores em Ciências da Saúde (DeCS): “probiotic”, “cardioprotective”, “Lactobacillus sp” e “Bifidobacterium sp”. A busca na Clinicaltrials.gov não revelou estudos sobre probióticos e Infarto Agudo do Miocárdio (IAM). Também foram analisadas patentes relacionadas a probióticos nas bases INPI, Espacenet e WIPO, encontrando patentes para Lactobacillus plantarum (n=5) e Lactobacillus acidophilus (n=2). Ao todo, 27 estudos foram identificados, sendo 9 incluídos na revisão. Os resultados mostram um aumento nas pesquisas sobre probióticos e DCV, mas ainda há a necessidade de estudos clínicos mais robustos sobre a prevenção de eventos isquêmicos cardíacos e um limitado potencial biotecnológico nessa área.

  • Open Access

    Prospecção tecnológica: perspectivas na utilização de Fridericia platyphylla para o tratamento de desordens cardiovasculares

    by Andressa Coelho Ferreira, Icaro Rodrigo Dutra Cunha, Jhonata Costa Moura, Raphael Furtado Marques, Mateus Balbino Barbosa de Carvalho, Ellen Caroline da Silva Penha, Carlos Alberto Alves Dias Filho, Carlos José Moraes Dias, Nivaldo de Jesus Silva Soares Junior, Raphael Ferreira Faleiro, et al.

    Introdução: As doenças cardiovasculares (DCVs) são uma das principais causas de morte globalmente, incluindo condições como hipertensão, insuficiência cardíaca e infarto. Estudos recentes têm explorado novas terapias, destacando o uso de compostos naturais de plantas. A Fridericia platyphylla mostrou potencial terapêutico para DCVs, devido às suas atividades antiinflamatória e vasorelaxante, sugerindo benefícios para a saúde cardiovascular. Objetivo: Avaliar as perspectivas do uso do extrato e/ou compostos isolados de F. platyphylla no tratamento de desordens cardiovasculares a partir de uma prospecção tecnológica. Metodologia: Foi realizada uma prospecção tecnológica baseada em pedidos de patentes nos bancos de dados do Instituto Nacional da Propriedade Industrial (INPI) do Brasil, European Patent Office (Espacenet), Google Patents, Derwent Innovations Index e World Intellectual Property Organization (WIPO). A pesquisa abrangeu patentes depositadas nos últimos 15 anos, utilizando descritores como Fridericia platyphylla, Fridericia platyphylla AND extrato, Fridericia platyphylla AND doenças cardiovasculares, Arrabidaea brachypoda, Arrabidaea brachypoda AND extrato, Arrabidaea brachypoda AND doenças cardiovasculares e seus correlatos em inglês. Resultados: A prospecção tecnológica de patentes entre 2008 e 2023 identificou 66 pedidos, com o maior número de depósitos ocorrendo em 2015, totalizando 20 patentes. A Universidade Estadual de Campinas (UNICAMP) foi a instituição com o maior número de patentes depositadas, seguida pela Universidade Federal do Maranhão e pela Universidade Estadual Paulista Julio de Mesquita Filho. Conclusão: Essas descobertas sugerem potencial terapêutico e tecnológico significativos na utilização do extrato de F. platyphylla e de seus compostos isolados, especialmente no contexto das doenças cardiovasculares.

  • Open Access

    Cardioprotective and vasorelaxant effects of carvacrol: a mechanistic approach

    by Vicenilma de Andrade Martins Costa, Daiane Pereira da Silva, Jhônata Costa Moura, Carlos José Moraes Dias, Herikson Araujo Costa, Antonio Carlos Romão Borges, Rachel Melo Ribeiro

    Cardiovascular disorders are the leading cause of morbidity and mortality worldwide. Therefore, it is beneficial to investigate new therapies for the control and treatment of these disorders. In this context, carvacrol emerges as a phytochemical with important therapeutic potential. Therefore, this article aims to discuss and describe the pharmacokinetic properties and main mechanisms that explain the effects of carvacrol on cardiovascular disorders. ADMET studies revealed that carvacrol has promising pharmacodynamic characteristics for cardiovascular treatments. Some studies showed that animals treated with carvacrol had a decrease in the infarct area, less collagen deposition, lower serum concentrations of cardiac injury markers, as well as a decrease in the expression of proteins involved in cellular apoptosis pathways, evidencing its cardioprotective role. However, most of the effects described are related to intraperitoneal and intravenous treatment in normotensive animals, being limited studies that investigated the effects of carvacrol by the oral route and demonstrating the need to continuation of the works with models of spontaneous hypertension, which would better mimic the systemic arterial hypertension observed in humans.

  • Open Access

    Efeito anti-hipertensivo do carvacrol envolve redução dos níveis séricos da enzima conversora de angiotensina em ratos submetidos ao treinamento físico aeróbio

    by Daiane Pereira da Silva, Jhônata Costa Moura, Vicenilma de Andrade Martins Costa, Rafael Cardoso Carvalho, Thiago Teixeira Mendes, Carlos José Moraes Dias, Lucas Martins França, Antonio Marcus de Andrade Paes, Marilene Oliveira da Rocha Borges, Antonio Carlos Romão Borges, et al.

    Introdução: O presente estudo foi realizado para investigar os efeitos do carvacrol sobre parâmetros hemodinâmicos, lipídicos e inibição da Enzima Conversora de Angiotensina em animais submetidos a treinamento físico aeróbio. Métodos: Os animais foram divididos aleatoriamente em grupos: Wistar- controle normotenso tratado com sorbitol; SHR- controle hipertenso tratado com sorbitol; SHR- tratado com losartana 50mg/kg (Los -50); SHR- tratado com Carvacrol 20 mg/kg (Carv-20); SHR- treinado com exercício aeróbio 60 minutos (Exer); SHR- tratado com Carvacrol (Exercarv) + 60 minutos de exercício aeróbio. O tratamento consitiu em quatro semanas com monitoramento de peso, consumo de ração, frequência cardíaca, pressão arterial sistólica, diastólica e média. Posterior ao tratamento, foram realizadas dosagens bioquímicas para parâmetros renais, hepaticos, lípidicos e dosagens séricas de ECA I. Foram analisadas reduções significativas nos níveis pressóricos dos animais hipertensos, após o protocol de itervenção. O grupo Exercarv, apresentou maiores reduções da PA, quando comparado aos demais grupos, apresentando valores pressóricos de PAS 122,0 ± 3,8 mmHg, PAD 97 ± 3,0 mmHg, PAM 105,5 ± 2,3 mmHg. Ainda, o grupo ExerCarv ocasionou reduções nos níveis de TG, CT, VLDL, TG/HDL e CT/HDL assim como, nos níveis de ureia e AST. Resultados: O procedimento isolado com carvacrol, assim como sua combinação com treinamento físico aeróbio, teve capacidade de reduzir atividade da ECA I comparando ao grupo SHR com p<0,001. Considerações finais: Um mês de tratamento com carvacrol combinado com exercício físico aeróbio apresentaram efeito antihipertensivo, relacionado a inibição da ECA I. Além disso, o tratamento melhorou os parâmetros renais, hepáticos e lipídicos.